<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140556</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008840</org_study_id>
    <secondary_id>7077</secondary_id>
    <nct_id>NCT00140556</nct_id>
  </id_info>
  <brief_title>Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer</brief_title>
  <official_title>Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David M. Brizel, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy (RT) with concurrent chemotherapy represents the state of the art in curative&#xD;
      intent treatment for locally advanced squamous carcinoma of the head and neck. Tumor hypoxia&#xD;
      and high levels of angiogenesis (blood vessel formation) are associated with treatment&#xD;
      failure. Preclinical models reveal that radiotherapy itself may induce tumor secretion of&#xD;
      vascular endothelial growth factor (VEGF). Curability may consequently be reduced by multiple&#xD;
      mechanisms. Over-expression of epidermal growth factor receptor (EGFR) also occurs commonly&#xD;
      and increases the risk of treatment failure. The addition of EGFR blockade to RT alone&#xD;
      increases the chance of a cure. Concurrent VEGF and EGFR blockade could be synergistic with&#xD;
      one another and improve the effectiveness of concurrent chemoradiation for advanced head and&#xD;
      neck cancer.&#xD;
&#xD;
      This study will add angiogenic and epidermal growth factor receptor (EGFR) blockade into an&#xD;
      established program of curative intent concurrent chemoradiation for locally advanced head&#xD;
      and neck cancer. The safety and effectiveness of delivering the drugs bevacizumab and Tarceva&#xD;
      in conjunction with twice daily irradiation and concurrent cisplatin (CDDP) chemotherapy will&#xD;
      be determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre Radiation Period:&#xD;
&#xD;
        -  Bevacizumab (10 mg/kg) on days -14 and 0, or&#xD;
&#xD;
        -  Tarceva (100 mg) daily from -14-0, or&#xD;
&#xD;
        -  Bevacizumab (10 mg/kg) on days -14 and 0; Tarceva (100 mg) daily from -14-0&#xD;
&#xD;
      Chemoradiation Period:&#xD;
&#xD;
        -  Radiotherapy may be delivered via conventional 2-D, conformal 3-D, or intensity&#xD;
           modulated (IMRT) technique as is clinically indicated. Radiotherapy and CDDP doses will&#xD;
           be delivered uniformly to all treatment cohorts:&#xD;
&#xD;
             -  RT: 1.25 Gy BID M-F with a 6 hour interfraction interval&#xD;
&#xD;
             -  Treatment break during week 4. Total dose 70 Gy/7 weeks&#xD;
&#xD;
             -  CDDP: 33 mg/m2 M-W on weeks 1 and 5 of RT with standard DUMC hydration and&#xD;
                anti-emetic regimens&#xD;
&#xD;
        -  Bevacizumab (10mg/kg): Monday of weeks 1, 3, 5, 7 of RT&#xD;
&#xD;
        -  Tarceva (100 mg): Daily for weeks 1-7 of treatment, except for days receiving CDDP&#xD;
&#xD;
      Safety Assessments:&#xD;
&#xD;
        -  Baseline and then weekly assessments of blood pressure and urine protein : creatinine&#xD;
           ratios during lead in and chemoRT phases of treatment&#xD;
&#xD;
        -  Baseline carotid Doppler ultrasound evaluation&#xD;
&#xD;
        -  Carotid Doppler ultrasound evaluation 1 month post-chemoRT&#xD;
&#xD;
      Efficacy Assessments:&#xD;
&#xD;
        -  MR Imaging/Spectroscopy to be done at baseline, end of lead-in phase, end of week 1 of&#xD;
           chemoRT, and end of chemoRT&#xD;
&#xD;
        -  Angiogenic and EGFR related cytokines. Specifically, blood samples will be obtained to&#xD;
           assay levels of VEGF, b-FGF, IL-8, D-dimer, EGF, TGF. These samples will be obtained on&#xD;
           the same dates as the MR studies with an additional set of samples obtained at the&#xD;
           midpoint of the lead in phase of treatment (day -7).&#xD;
&#xD;
      Clinical Assessments:&#xD;
&#xD;
        -  All patients will undergo a minimum of once weekly interval history and physical&#xD;
           examination including fiberoptic pharyngoscopy/laryngoscopy when indicated in the&#xD;
           Department of Radiation Oncology to monitor for side effects and response to treatment&#xD;
           as per standard routine for the care of patients with head and neck cancer.&#xD;
&#xD;
        -  Patient compliance with Tarceva administration monitored via diary MRI/MRS (Magnetic&#xD;
           Resonance Spectroscopy) DE-MRI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Resolution</measure>
    <time_frame>Within 30 days of completing RT</time_frame>
    <description>Complete response (resolution) of tumor on clinical exam.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Regional Control</measure>
    <time_frame>1 yr following chemoradiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure Free Survival</measure>
    <time_frame>3 yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Pharynx Cancer</condition>
  <arm_group>
    <arm_group_label>ChemoRadiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>External beam radiation daily (M-F)</description>
    <arm_group_label>ChemoRadiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin week 1 and 5 of radiation</description>
    <arm_group_label>ChemoRadiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation</description>
    <arm_group_label>ChemoRadiotherapy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib daily during radiation</description>
    <arm_group_label>ChemoRadiotherapy</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced squamous carcinoma of the head and neck (AJCC stages II/IV, M0, and&#xD;
             excluding T1N1 and T1N2) undergoing curative intent concurrent chemoradiation.&#xD;
&#xD;
          -  Previous treatment of any sort other than a biopsy is not allowed.&#xD;
&#xD;
          -  Eligible anatomic sites:&#xD;
&#xD;
               -  oral cavity&#xD;
&#xD;
               -  oropharynx&#xD;
&#xD;
               -  hypopharynx&#xD;
&#xD;
               -  supraglottic&#xD;
&#xD;
               -  glottic larynx&#xD;
&#xD;
          -  KPS &gt; 60&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nasopharynx primary&#xD;
&#xD;
          -  History of malignancy other than basal cell skin cancer.&#xD;
&#xD;
          -  History of claudication, bleeding, or thromboembolic disorders. Patients receiving&#xD;
             heparin or Coumadin therapy are ineligible.&#xD;
&#xD;
          -  Primary tumor or lymph node encasement of the carotid artery&#xD;
&#xD;
          -  Blood pressure of &gt;150/100 mmHg&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure&#xD;
&#xD;
          -  History of myocardial infarction within 6 months&#xD;
&#xD;
          -  History of stroke within 6 months&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to Day 0; anticipation of need for major surgical procedure during the course of&#xD;
             the study.&#xD;
&#xD;
          -  Minor surgical procedures, fine needle aspirations, or core biopsies within 7 days&#xD;
             prior to Day 0&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or lactating&#xD;
&#xD;
          -  Urine protein : creatinine ratio â‰¥ 1.0 at screening&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to Day 0&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  AST, ALT, or bilirubin &gt; 1.5 x normal&#xD;
&#xD;
          -  PT or PTT &gt; 1.5 x normal&#xD;
&#xD;
          -  Platelets &lt; 100,000&#xD;
&#xD;
          -  WBC &lt; 2000&#xD;
&#xD;
          -  Hgb &lt; 10&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/hr&#xD;
&#xD;
          -  Refusal to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Brizel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology; Duke University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Radiation Oncology; Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999 Nov;53(2):113-7.</citation>
    <PMID>10665787</PMID>
  </reference>
  <reference>
    <citation>Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998 Jun 18;338(25):1798-804.</citation>
    <PMID>9632446</PMID>
  </reference>
  <reference>
    <citation>Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):349-53.</citation>
    <PMID>11567808</PMID>
  </reference>
  <reference>
    <citation>Dewhirst MW, Poulson JM, Yu D, Sanders L, Lora-Michiels M, Vujaskovic Z, Jones EL, Samulski TV, Powers BE, Brizel DM, Prosnitz LR, Charles HC. Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):480-91.</citation>
    <PMID>15667971</PMID>
  </reference>
  <reference>
    <citation>Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004 May;5(5):429-41.</citation>
    <PMID>15144951</PMID>
  </reference>
  <results_reference>
    <citation>Craciunescu O, Brizel D, Cleland E, Yoo D, Muradyan N, Carroll M, Barboriak D, MacFall J. Dynamic contrast enhanced-MRI in head and neck cancer patients: variability of the precontrast longitudinal relaxation time (T10). Med Phys. 2010 Jun;37(6):2683-92.</citation>
    <PMID>20632579</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <results_first_submitted>August 19, 2010</results_first_submitted>
  <results_first_submitted_qc>August 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2011</results_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>David M. Brizel, MD</investigator_full_name>
    <investigator_title>Professor, Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>erlotinib</keyword>
  <keyword>Tarceva</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <keyword>pharynx cancer</keyword>
  <keyword>tonsil cancer</keyword>
  <keyword>hyperfractionation</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>epidermal growth factor</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>cancer of the head and neck</keyword>
  <keyword>upper aerodigestive tract neoplasms</keyword>
  <keyword>pharynx neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Pharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the multidisciplinary ENT or Radiation Oncology Clinics between September 2005 and February 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre Radiation Period: Avastin / Tarceva</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Chemoradiotherapy Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Feeding Tube</title>
          <description>Feeding tube present before start of treatment</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Feeding Tube Present Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Feeding Tube at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Resolution</title>
        <description>Complete response (resolution) of tumor on clinical exam.</description>
        <time_frame>Within 30 days of completing RT</time_frame>
        <population>2 participants had occult primaries, thus were not included in clinical complete response</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study Population</title>
          </group>
        </group_list>
        <measure>
          <title>Tumor Resolution</title>
          <description>Complete response (resolution) of tumor on clinical exam.</description>
          <population>2 participants had occult primaries, thus were not included in clinical complete response</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Regional Control</title>
        <time_frame>1 yr following chemoradiation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Failure Free Survival</title>
        <time_frame>3 yrs</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Acute adverse events through 30 days post end of treatment. Possibly related to chemoradiotherapy greater than grade 1. Late radiotherapy related adverse events through 2 years.</time_frame>
      <desc>Toxicity assessment weekly during treatment, and post treatment at 1 month and every 3 months through year 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever (in the absence of neutropenia)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dental, periodontal disease</sub_title>
                <description>Late radiation effect</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mucositis, Oropharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucosal Infection</sub_title>
                <description>Oral candiasis</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <description>Late radiation effect</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Soft Tissue Necrosis</sub_title>
                <description>Late radiation effect</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Radiation Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Erlotinib (Tarceva) rash</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Brizel, MD</name_or_title>
      <organization>Duke University Medical Center, Dept Radiation Oncology</organization>
      <phone>919 668-5637</phone>
      <email>david.brizel@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

